BRAF and cancer: As such, tyrosine kinase inhibitors (TKIs) targeting BRAF and MEK proteins block the constitutive activation of the MAPK pathway in patients with BRAF-mutated melanoma [3], therefore reducing maintenance, development or dissemination of the cancer.